Literature DB >> 8022414

Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.

C M Seynaeve1, M G Kazanietz, P M Blumberg, E A Sausville, P J Worland.   

Abstract

UCN-01 (7-hydroxystaurosporine) has been demonstrated to be a potent inhibitor of tumor cell growth both in cell culture and with in vivo xenograft models. The ability of UCN-01 to inhibit the kinase activity of recombinant protein kinase C (PKC) isozymes alpha, beta, gamma, delta, epsilon, and zeta was characterized using an in vitro kinase assay. Two distinct groups of isozymes could be defined on the basis of relative potency of kinase inhibition. UCN-01 was 15-20-fold more potent for inhibition of the Ca(2+)-dependent isozymes, compared with the Ca(2+)-independent isozymes. In contrast, UCN-02 (the diastereomer of UCN-01) and staurosporine exhibited less ability to discriminate between Ca(2+)-dependent and -independent isozymes. PKC-zeta was not inhibited by UCN-01, UCN-02, or staurosporine. IC50 values for UCN-01 inhibition of the Ca(2+)-dependent PKC-alpha, -beta, and -gamma were 29, 34, and 30 nM, respectively, and for the Ca(2+)-independent PKC-delta and -epsilon were 530 and 590 nM, respectively. IC50 values for staurosporine inhibition of the isozymes alpha, beta, and gamma were 58, 65, and 49 nM, respectively, and for the isozymes delta and epsilon were 325 and 160 nM, respectively. UCN-02 was significantly less potent for the inhibition of PKC-alpha, -beta, -gamma, -delta, and -epsilon (IC50 values of 530, 700, 385, 2800, and 1200 nM, respectively). An analysis of the inhibition by UCN-01 and staurosporine of the kinase activity of PKC-alpha and -delta indicated mixed inhibition kinetics. Increasing the ATP concentration resulted in decreased potency, as shown by increased IC50 values. In contrast, increasing the peptide substrate concentration resulted in increased potency, as shown by decreased IC50 values. Increasing concentrations of myelin basic protein as a PKC-alpha or -delta substrate also caused increased potency of inhibition by UCN-01. Because of the competitive nature of inhibition with respect to ATP and the uncompetitive nature with respect to substrate, the concentrations of these substrates can have dramatically different effects on the degree of inhibition observed. These data also suggest that UCN-01 may be an important tool for the dissection of PKC isozyme contributions to signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8022414

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

1.  Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase.

Authors:  A Rahman; K N Anwar; S Uddin; N Xu; R D Ye; L C Platanias; A B Malik
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 2.  Protein kinase C inhibitors.

Authors:  Helen C Swannie; Stanley B Kaye
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

3.  Intracellular signals that control cell proliferation in mammalian balance epithelia: key roles for phosphatidylinositol-3 kinase, mammalian target of rapamycin, and S6 kinases in preference to calcium, protein kinase C, and mitogen-activated protein kinase.

Authors:  M Montcouquiol; J T Corwin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

4.  Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion.

Authors:  M Bredel; I F Pollack; J M Freund; J Rusnak; J S Lazo
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 5.  Side-effects of protein kinase inhibitors on ion channels.

Authors:  Youn Kyoung Son; Hongzoo Park; Amy L Firth; Won Sun Park
Journal:  J Biosci       Date:  2013-12       Impact factor: 1.826

Review 6.  Cell cycle kinases as therapeutic targets for cancer.

Authors:  Silvia Lapenna; Antonio Giordano
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

7.  Cellular pharmacology of protein kinase Mζ (PKMζ) contrasts with its in vitro profile: implications for PKMζ as a mediator of memory.

Authors:  Alyssa X Wu-Zhang; Cicely L Schramm; Sadegh Nabavi; Roberto Malinow; Alexandra C Newton
Journal:  J Biol Chem       Date:  2012-02-29       Impact factor: 5.157

Review 8.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

9.  Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.

Authors:  M Firdos Ziauddin; Wen-Shuz Yeow; Justin B Maxhimer; Aris Baras; Alex Chua; Rishindra M Reddy; Wilson Tsai; George W Cole; David S Schrump; Dao M Nguyen
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

Review 10.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.